AI-Driven Surge in Digital Health VC Funding Reaches $7.4 Billion in H1 2026

Venture capital funding for digital health startups has seen a notable rebound, driven by advancements in AI technology. According to Rock Health's analysis, digital health companies raised $7.4 billion in the first half of 2026, marking a $1 billion increase from the same period in 2025, when $6.4 billion was raised. This surge highlights the growing investor confidence in the sector, particularly in AI-driven solutions.

Rock Health's data shows that there were 244 deals in H1 2026, with investors pouring $3.2 billion into the sector in Q2, just shy of the $4.2 billion invested in Q1. The concentration of capital is evident, as a small number of megadeals-defined as financings of $100 million or more-dominated the funding landscape.

Megadeals Drive Investment Concentration

In the first half of 2026, 19 companies secured 20 megadeals, accounting for 45% of all capital invested. These deals represent a significant portion of the total funding, with just over 8% of all deals absorbing nearly half of the deployed capital. Notable megadeals include:

• Whoop: Raised $575 million in Series G funding, with Abbott joining as an investor.
• OpenEvidence: Secured $250 million to expand its reach among healthcare providers.
• Grow Therapy: Acquired $150 million to build out enterprise partnerships.
• Verily: Received $300 million to accelerate its AI roadmap and transition into an independent company.
• Talkiatry: Closed a $210 million Series D round to expand telepsychiatry services.
• eMed: Raised $200 million, achieving a $2 billion valuation.
• Forus: Secured $160 million to build the foundation for modern medical infrastructure.

These megadeals underscore the strategic bets venture capitalists are placing on innovative digital health companies that leverage AI to address critical healthcare challenges. The concentration of capital in these deals also reflects a cautious approach, with investors focusing on high-potential, well-established firms.

Investment Implications

The surge in AI-driven investments has significant implications for both the digital health sector and broader healthcare markets. As AI technology continues to advance, it is reshaping the competitive landscape and resetting expectations for what is possible in healthcare delivery and administration.

CVS Health, for example, is positioning itself as an "AI front door" to healthcare, aiming to automate administrative tasks and address staffing shortages. This strategic move highlights the potential of AI to streamline operations and improve patient care, aligning with the broader trends observed in digital health funding.

For investors, the key takeaway is the growing importance of AI in driving value and innovation in the healthcare sector. The concentration of capital in megadeals suggests that investors are prioritizing companies with robust AI capabilities and clear pathways to market adoption. As the industry continues to evolve, staying attuned to these trends will be crucial for capturing opportunities and managing risks.

The rebound in digital health funding, fueled by AI advancements, signals a promising future for the sector. However, investors must remain vigilant, balancing their optimism with a critical assessment of each company's technological capabilities and market potential.